RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
TG Therapeutics Stock

TG Therapeutics Net Income 2024

TG Therapeutics Net Income

23.47 M USD

Ticker

TGTX

ISIN

US88322Q1085

WKN

A1JXW7

In 2024, TG Therapeutics's profit amounted to 23.47 M USD, a 85.17% increase from the 12.67 M USD profit recorded in the previous year.

The TG Therapeutics Net Income history

YEARNET INCOME (undefined USD)
2029e714.53
2028e608.93
2027e402.52
2026e285.81
2025e154.02
2024e23.47
202312.67
2022-198.34
2021-348.1
2020-279.38
2019-172.87
2018-173.48
2017-118.48
2016-78.25
2015-62.95
2014-55.78
2013-20.48
2012-18.07
2011-0.85
20100.62
2009-2.79
2008-4.27
2007-12.03
2006-9.69
2005-19.32
2004-6.48

TG Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into TG Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by TG Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects TG Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of TG Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into TG Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing TG Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on TG Therapeutics’s growth potential.

TG Therapeutics Revenue, EBIT and net profit per share

DateTG Therapeutics RevenueTG Therapeutics EBITTG Therapeutics Net Income
2029e1.5 B undefined0 undefined714.53 M undefined
2028e1.32 B undefined675.65 M undefined608.93 M undefined
2027e1.04 B undefined477.05 M undefined402.52 M undefined
2026e760.8 M undefined218.89 M undefined285.81 M undefined
2025e551.82 M undefined131.68 M undefined154.02 M undefined
2024e335.86 M undefined16.38 M undefined23.47 M undefined
2023233.66 M undefined20.63 M undefined12.67 M undefined
20222.79 M undefined-192.84 M undefined-198.34 M undefined
20216.69 M undefined-344.77 M undefined-348.1 M undefined
2020150,000 undefined-273.59 M undefined-279.38 M undefined
2019150,000 undefined-169.06 M undefined-172.87 M undefined
2018150,000 undefined-174.4 M undefined-173.48 M undefined
2017150,000 undefined-118.71 M undefined-118.48 M undefined
2016150,000 undefined-78.97 M undefined-78.25 M undefined
2015150,000 undefined-63.18 M undefined-62.95 M undefined
2014150,000 undefined-55.72 M undefined-55.78 M undefined
2013150,000 undefined-20.17 M undefined-20.48 M undefined
201220,000 undefined-25.8 M undefined-18.07 M undefined
20110 undefined-880,000 undefined-850,000 undefined
20100 undefined-2.02 M undefined620,000 undefined
20090 undefined-1.77 M undefined-2.79 M undefined
20080 undefined-4.41 M undefined-4.27 M undefined
20070 undefined-12.14 M undefined-12.03 M undefined
20060 undefined-10 M undefined-9.69 M undefined
20050 undefined-7.47 M undefined-19.32 M undefined
20040 undefined-6.14 M undefined-6.48 M undefined

TG Therapeutics stock margins

The TG Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of TG Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for TG Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the TG Therapeutics's sales revenue. A higher gross margin percentage indicates that the TG Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the TG Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the TG Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the TG Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the TG Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the TG Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

TG Therapeutics Margin History

TG Therapeutics Gross marginTG Therapeutics Profit marginTG Therapeutics EBIT marginTG Therapeutics Profit margin
2029e93.95 %0 %47.6 %
2028e93.95 %51.19 %46.13 %
2027e93.95 %45.83 %38.67 %
2026e93.95 %28.77 %37.57 %
2025e93.95 %23.86 %27.91 %
2024e93.95 %4.88 %6.99 %
202393.95 %8.83 %5.42 %
202290.32 %-6,911.83 %-7,108.96 %
202188.19 %-5,153.51 %-5,203.29 %
202093.95 %-182,393.32 %-186,253.33 %
201993.95 %-112,706.67 %-115,246.66 %
201893.95 %-116,266.66 %-115,653.32 %
201793.95 %-79,140 %-78,986.66 %
201693.95 %-52,646.67 %-52,166.66 %
201593.95 %-42,120 %-41,966.67 %
201493.95 %-37,146.67 %-37,186.66 %
201393.95 %-13,446.67 %-13,653.33 %
201293.95 %-129,000 %-90,350 %
201193.95 %0 %0 %
201093.95 %0 %0 %
200993.95 %0 %0 %
200893.95 %0 %0 %
200793.95 %0 %0 %
200693.95 %0 %0 %
200593.95 %0 %0 %
200493.95 %0 %0 %

TG Therapeutics Aktienanalyse

What does TG Therapeutics do?

TG Therapeutics Inc is a biopharmaceutical company based in New York City, USA. The company was founded in 2012 and focuses on the development and commercialization of innovative therapy options for various types of cancer and autoimmune diseases. TG Therapeutics was founded as a result of a collaboration between Michael S. Weiss, an experienced investment banker and biotechnology manager, and Laurence N. Charous, an oncologist and clinical researcher. The company has roots in two predecessor companies: Manhattan Pharmaceuticals and LFB Biotechnologies. Both had failed, and TG rose from their remains. TG Therapeutics' business model is to develop a new therapy option by combining drugs of different drug classes that target the needs of patients with specific cancer conditions. The dual blockade approach, which simultaneously inhibits various signaling pathways that sustain tumor cells, is particularly promising. TG Therapeutics operates a diversified portfolio strategy and has several drug candidates in different stages of development for numerous cancer conditions, including diffuse large B-cell lymphoma, chronic lymphocytic leukemia, and multiple myeloma, as well as autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus. TG Therapeutics' main products for cancer treatments currently are umapalisib and umbralisib, both of which are PI3K delta inhibitors and are being developed for the treatment of non-Hodgkin lymphomas and chronic lymphocytic leukemia. TG-1101 (Ublituximab) is a CD20-targeted antibody therapy used in lymphomas and autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus. TG Therapeutics' research and development efforts are driven by an experienced team of oncologists and scientists, including CEO Michael S. Weiss. The company maintains close relationships with academic institutions and research facilities. TG Therapeutics holds a broad patent portfolio covering technologies and compounds that can be used in cancer and autoimmune disease treatment. In 2020, TG Therapeutics' revenue reached approximately $109 million, compared to $14 million in the previous year. This increase in revenue was due to the sales of umbralisib. However, the company has not yet received FDA approval for any of its drugs in the US. TG Therapeutics expects that the future success of the company will be based on the clinical activity of its pipeline, market acceptance of its products, and successful completion of studies and regulatory approvals. As of December 31, 2020, TG Therapeutics had 248 employees. The company's leading body, the board of directors, consists of an experienced team of executives and advisors, including Chairman and CEO Michael S. Weiss, CFO Sean A. Power, CMO Adam D. Feuerstein, and COO Scott T. Smith. TG Therapeutics has had a tumultuous past, but the company can now look forward to a promising pipeline and a very strong financial position. The research and development of this biopharmaceutical company are promising, and it remains to be seen which of the research products will actually break through and be introduced to the market. TG Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Net Income Details

Understanding TG Therapeutics's Profit Margins

The profit margins of TG Therapeutics represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of TG Therapeutics's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating TG Therapeutics's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

TG Therapeutics's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When TG Therapeutics’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about TG Therapeutics stock

How much profit has TG Therapeutics made this year?

TG Therapeutics has made 23.47 M USD this year.

How has the profit developed compared to last year?

The profit has increased by 85.17% compared to last year increased

What impact do the earnings have on the shareholders?

An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.

How does TG Therapeutics publish its earnings?

TG Therapeutics publishes its earnings in the form of quarterly or annual reports.

Which financial indicators are included in the quarterly or annual reports?

The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.

Why is it important for investors to know the earnings of TG Therapeutics?

The profits of TG Therapeutics are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.

How can one learn more about the earnings of TG Therapeutics?

You can learn more about the earnings of TG Therapeutics by reviewing the quarterly or annual reports or following the company presentations.

How much dividend does TG Therapeutics pay?

Over the past 12 months, TG Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, TG Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of TG Therapeutics?

The current dividend yield of TG Therapeutics is .

When does TG Therapeutics pay dividends?

TG Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of TG Therapeutics?

TG Therapeutics paid dividends every year for the past 0 years.

What is the dividend of TG Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is TG Therapeutics located?

TG Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von TG Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of TG Therapeutics from 11/20/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/20/2024.

When did TG Therapeutics pay the last dividend?

The last dividend was paid out on 11/20/2024.

What was the dividend of TG Therapeutics in the year 2023?

In the year 2023, TG Therapeutics distributed 0 USD as dividends.

In which currency does TG Therapeutics pay out the dividend?

The dividends of TG Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The TG Therapeutics stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von TG Therapeutics

Our stock analysis for TG Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of TG Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.